BRBR Investors Encouraged to Seek Lead Plaintiff Role in BellRing Brands Securities Class Action Case with Johnson Fistel — Neutral
BRBR GlobeNewsWire — January 26, 2026SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired BellRing Brands, Inc. (NYSE: BRBR) securities between November 19, 2024 and August 4, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws.
Dynex Capital, Inc. (DX) Q4 2025 Earnings Call Transcript — Neutral
DX Seeking Alpha — January 26, 2026Dynex Capital, Inc. (DX) Q4 2025 Earnings Call Transcript
Cerrado Gold Inc. (CERT:CA) Discusses Purported Unfavourable Opinion of Environmental Impact Assessment for Lagoa Salgada Project Transcript — Neutral
CERT CRDOF Seeking Alpha — January 26, 2026Cerrado Gold Inc. (CERT:CA) Discusses Purported Unfavourable Opinion of Environmental Impact Assessment for Lagoa Salgada Project Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript — Neutral
SRPT Seeking Alpha — January 26, 2026Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Affirm Is Expanding Buy Now, Pay Later Services for Rent Payments — Neutral
AFRM MarketBeat — January 26, 2026Over the past month, financial stocks have been getting hammered. Of the S&P 500's 11 sectors, the group has performed the worst with a loss of 2.73%.
Discover hidden Costco member perks beyond bulk shopping: exclusive travel deals, auto discounts, prescription savings and professional home services.
Costco's popular bargain meal at center of new lawsuit — Negative
COST Fox Business — January 26, 2026Costco faces a class-action lawsuit over alleged false "no preservatives" claims on its popular Kirkland rotisserie chicken, court documents show.
Zoom's 'hidden gem' investment in Anthropic could be worth $2 billion to $4 billion, analysts say — Positive
ZM CNBC — January 26, 2026Shares of Zoom popped on Monday after analysts at Baird estimated that the company's investment in the AI startup Anthropic could be worth billions. Anthropic announced a partnership with Zoom and revealed that Zoom Ventures had invested in the company in May 2023.
Why Karooooo (KARO) Might be Well Poised for a Surge — Positive
KARO Zacks Investment Research — January 26, 2026Karooooo Ltd. (KARO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Rising for Interactive Brokers (IBKR): Will It Gain? — Positive
IBKR Zacks Investment Research — January 26, 2026Interactive Brokers Group, Inc. (IBKR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
INVESTOR ALERT: Investigation of Beta Bionics, Inc. (BBNX) by Holzer & Holzer, LLC — Neutral
BBNX GlobeNewsWire — January 26, 2026ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) complied with federal securities laws. On January 8, 2026, Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results, reporting that new patient starts, or the total number of individuals who have initiated use of the iLet Bionic Pancreas System, are expected to be below analyst estimates for the fourth quarter. Following this news, the price of the Company's stock dropped.
INVESTOR ALERT: Investigation of Mereo BioPharma Group plc (MREO) by Holzer & Holzer, LLC — Neutral
MREO GlobeNewsWire — January 26, 2026ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) complied with federal securities laws. On December 29, 2025, Mereo announced the results from its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, revealing that, “[n]either study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.” Following this news, the price of the Company's stock dropped.
USA Rare Earth Is Surging. A Big Government Funding Deal Is Lifting the Stock — Positive
USAR Investopedia — January 26, 2026USA Rare Earth (USAR) is starting the week on a high note with a public-private funding deal that is lifting the company's shares.
Why Owens Corning (OC) is Poised to Beat Earnings Estimates Again — Positive
OC Zacks Investment Research — January 26, 2026Owens Corning (OC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why eBay (EBAY) is Poised to Beat Earnings Estimates Again — Positive
EBAY Zacks Investment Research — January 26, 2026eBay (EBAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Skyward (SKWD) Beat Estimates Again in Its Next Earnings Report? — Positive
SKWD Zacks Investment Research — January 26, 2026Skyward (SKWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again — Positive
VCYT Zacks Investment Research — January 26, 2026Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Entergy (ETR) Beat Estimates Again in Its Next Earnings Report? — Positive
ETR Zacks Investment Research — January 26, 2026Entergy (ETR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will ADM (ADM) Beat Estimates Again in Its Next Earnings Report? — Positive
ADM Zacks Investment Research — January 26, 2026ADM (ADM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Arhaus, Inc. (ARHS) Beat Estimates Again in Its Next Earnings Report? — Positive
ARHS Zacks Investment Research — January 26, 2026Arhaus, Inc. (ARHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
